Orlando Clinical Research Center

Orlando, Florida 32908

16 studies enrolling now · 248 studies all time

What they study most

Acute Kidney Injury, Advanced Malignancies, Antithrombotic, Asthma, Attention Deficit Hyperactivity Disorder (ADHD), Autoimmune and Chronic Inflammatory Diseases, Bacterial Infections, Binge-Eating Disorder Disorder, COVID 19, COVID-19, Cardiac Failure, Chronic Hepaititis B Infections

Studies at this site

• A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems — Recruiting now
• A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib — Recruiting now
• Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib — Recruiting now
• A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function — Recruiting now
• A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment — Recruiting now
• A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease — Recruiting now
• Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants — Recruiting now
• A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. — Recruiting now
• A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function — Recruiting now
• A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function — Recruiting now
• A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function — Recruiting now
• Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function — Recruiting now
• Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function — Recruiting now
• Clofutriben Pharmacokinetics in Patients With Impaired Renal Function — Recruiting now
• A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment — Recruiting now
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function — Completed
• A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment — Completed
• A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function — Completed
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function — Completed
• A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease — Starting soon
• A Research Study on Etavopivat in Participants With and Without Liver Disease — Completed
• A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function — Running, not enrolling
• A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment. — Completed
• A Study of LY3502970 in Participants With Impaired and Normal Liver Function — Completed
• An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage — Completed
• A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose — Completed
• A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment — Completed
• A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function — Completed
• A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. — Completed
• A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) — Completed
• A Study to Evaluate EDG-7500 in People With Renal Impairment — Completed
• A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function — Completed
• A Varegacestat Hepatic Impairment Study — Completed
• Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls — Completed
• Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls — Completed
• A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body — Completed
• A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose — Completed
• Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function — Completed
• An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function — Completed
• Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function — Completed
• A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function — Completed
• A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment — Completed
• A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function — Completed
• A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment — Completed
• A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis — Completed
• A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. — Completed
• A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment — Completed
• A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants — Completed
• A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function — Completed
• A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment — Completed